Volume | 11,672,448 |
|
|||||
News | - | ||||||
Day High | 0.18 | Low High |
|||||
Day Low | 0.1563 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Jaguar Health Inc | JAGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.1622 | 0.1563 | 0.18 | 0.1699 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,453 | 11,672,448 | $ 0.1663327 | $ 1,941,510 | - | 0.0512 - 1.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:30:25 | 30 | $ 0.1768 | USD |
Jaguar Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.14M | 50.76M | - | 9.76M | -41.3M | -0.81 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jaguar Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JAGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1442 | 0.1986 | 0.1423 | 0.1737 | 56,080,514 | 0.0325 | 22.54% |
1 Month | 0.0725 | 0.254 | 0.071 | 0.1447429 | 89,805,479 | 0.1042 | 143.72% |
3 Months | 0.10 | 0.254 | 0.0512 | 0.117941 | 62,646,642 | 0.0767 | 76.70% |
6 Months | 0.33 | 0.5144 | 0.0512 | 0.1254633 | 33,540,723 | -0.1533 | -46.45% |
1 Year | 0.555 | 1.22 | 0.0512 | 0.1608047 | 18,197,471 | -0.3783 | -68.16% |
3 Years | 120.75 | 228.00 | 0.0512 | 21.48 | 9,098,289 | -120.57 | -99.85% |
5 Years | 1,160.25 | 1,273.50 | 0.0512 | 71.07 | 9,667,648 | -1,160.07 | -99.98% |
Jaguar Health Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. |